Therapeutic Strategy Details
| Strategy ID: | S03 |
| Strategy: | anti-inflammatory |
| Other Terms: | Anti-inflammatory; Anti-fibrosis; Anti-oxidative stress; Anti-inflammatory; Immunotherapy; Anti-inflammatory; Anti-apoptosis; Anti-inflammatory; Anti-inflammatory; Anti-oxidative stress; Anti-inflammatory; Anti-fibrosis; Anti-oxidative stress; Anti-inflammatory; Anti-apoptosis; Anti-inflammatory; Anti-oxidative stress; Anti-fibrosis; Enhance lipid metabolism; Anti-inflammatory; Anti-fibrosis; Enhance lipid metabolism; Anti-inflammatory; Anti-inflammatory; Immunosuppressive; Anti-inflammatory; inducing apoptosis in those cells; Anti-inflammatory; Improve insulin resistance; Enhance lipid metabolism; Regulating intestinal flora; Anti-hypertensive; Anti-oxidative stress; Anti-inflammatory; Anti-fibrosis; Improve insulin resistance; Enhance lipid metabolism; Anti-inflammatory; anti-inflammatory; anti-oxidative stress; Anti-fibrosis; Anti-inflammatory; Anti-apoptosis; Anti-hypertensive; Anti-inflammatory; Anti-fibrosis; Anti-inflammatory; Immunotherapy; Anti-hypertensive; Anti-oxidative stress; Anti-inflammatory; Anti-inflammatory; Improve insulin resistance; Anti-inflammatory; Anti-oxidative stress; Anti-apoptosis; Anti-hypertensive; Anti-inflammatory; Anti-inflammatory; Lifestyle measures; non-steroidal anti-inflammatory agents (NSAIDs); Anti-inflammatory; Anti-fibrosis; Enhance lipid metabolism; Regulating intestinal flora; Improve insulin resistance; Enhance lipid metabolism; Anti-inflammatory; Enhance lipid metabolism; Anti-oxidative stress; Anti-inflammatory; anti-inflammatory; Anti-fibrosis; Anti-inflammatory; Cell therapy; Anti-inflammatory; Anti-fibrosis; Anti-inflammatory; Anti-fibrosis; Anti-apoptosis; Immunotherapy; Anti-inflammatory; Improve insulin resistance; Anti-oxidative stress; Anti-inflammatory; Anti-fibrosis; non-steroidal anti-inflammatory drugs (NSAIDs) treatment; Anti-fibrosis; Anti-inflammatory; Anti-hypertensive; Anti-oxidative stress; Anti-inflammatory; Anti-fibrosis; Anti-apoptosis; Anti-fibrosis; Anti-inflammatory; Anti-oxidative stress; Anti-inflammatory renoprotection; anti-inflammatory effect; Enhance lipid metabolism; Anti-inflammatory; Anti-fibrosis; Anti-oxidative stress; Anti-inflammatory; Anti-oxidative stress; Anti-lipogenesis; Anti-fibrosis |
| Related Targets: | NF-κB; TNF-α; NF-κB; FGF23; MAPK; caspase-3; Bcl-2; Nrf2; HO-1; p38 MAPK; JNK; FXR; TNF-α; IL-1β; IL-6; AMPK; PPAR; IL-1β; IL-6; TNF-α; ACE; Smad4; PKD1; p62; mTOR; AMPK; HIF; HIF; Smad2/3; Smad2/3; VEGFA; IL-6; MAPK; IL-1β; EGFR; TLR4; IL-6; Wnt/β-catenin; HO-1; NF-κB; TLR4; NF-κB; NF-κB; STAT3; JAK2; NOX4; NF-κB; Nrf2; SGLT2; HIF; SIRT1; JAK1; JAK2; TLR4; Smad2/3; IL-17; IL-6; PI3K; AKT; IL-6; IL-1β; TNF-α; TGF-β; EGF; IL-17; AMPK; NOX4; caspase-3; NOX4; NLRP3; caspase-1; IL-1β; ERK; JNK; p38 MAPK; NLRP3; NLRP3; NF-κB; HIF; hepcidin |
| Related Drugs: | MRI-1867; JD5037; 1400W; prednisolone; methotrexate; eldecalcitol; teriparatide; denosumab; streptozotocin; chloroquine; dexamethasone; 5-aminosalicylates; azathioprine; methotrexate; Glatiramer acetate; Glatiramer; paricalcitol; Oleuropein; methyl corosolate; uvaol; oleanolic acid; phenolic-rich açaí seed extract; BML-111; ML385; Recombinant thrombomodulin; obeticholic acid (OCA; 6-ethyl chenodeoxycholic acid); tropifexor; nidufexor; Tripterygium wilfordii Hook F; C4BP(x3b2; -); cyclophosphamide; methylprednisolone; cyclophosphamide; tripterygium wilfordii multiglycosides; prednisone; Astragalus; Salvia miltrorrhiza; Polygala fallax Hemsl; compound Sanqi granules; metformin; Okadaic acid; berberine; NOX5 siRNA; Tectorigenin; gentamicin; miR-218 inhibitor; methylprednisolone; prednisolone; mycophenolate mofetil; cyclosporine A; cyclophosphamide; rituximab; azathioprine; tacrolimus; propionate; Hirudin; Hsub2/subS; NO; Hsub2/subSxa0; xa0; NO; USC; prednisolone; mizoribine; angiotensin-converting enzyme inhibitors; steroids; cyclophosphamide; Korean red ginseng; Panax ginseng C.A. Mey.; streptozotocin; probiotics; Lactobacillus; Bifidobacterium; Sodium-glucose cotransporter 2 inhibitors; SGLT2 inhibitors; intravenous immunoglobulins; glucocorticoids; cyclophosphamide; azathioprine; Cyanidin-3-glucoside; Curcumin; quercetin; formononetin; calycosin; 7-O-methylisomucronulatol; quercetin; 1,25sub2/subDsub3/sub; parthenolide; insulin; Tocilizumab; Oral prednisolone; Astragaloside IV; Akebia saponin D; dioscin; streptozocin; Baicalin; tegafur/gimeracil/oteracil; furosemide; prednisolone; methylprednisolone; prednisolone; steroid; allopurinol; β-Caryophyllene; Colchicine; systemic/intra-articular corticosteroids; non-steroidal anti-inflammatory agents; IL-1 inhibitors; immunosuppressive therapy; STZ; dapagliflozin; streptozocin; Ergosterol; Streptozotocin; corticosteroids; cyclophosphamide; tofacitinib; inulin; Sodium-glucose cotransporter 2 inhibitors; curcumin; camptothecin; streptomycin; JAK inhibitors; ruxolitinib; Plantamajoside; methylprednisolone; intravenous immunoglobulin; vitamin D receptor agonists; paricalcitol; Am80; all-trans retinoic acid; Capsicum annuum L.; HPMA copolymer-based dexamethasone prodrug; PEG-based dexamethasone prodrug; glucocorticoid; cyclophosphamide; psoralen; Caffeine; glucocorticoids; Streptozotocin; paramylon; Campath; IV steroid; IV antibiotics; clindamycin; cMet agonistic antibody; short-chain fatty acids; acetate; propionate; butyrate; GPR43 agonist; Infliximab; corticosteroids; secukinumab; prednisolone; methylprednisolone; Cyclophosphamide; non-steroidal anti-inflammatory drugs; methotrexate; steroid; Dexamethasone; Tiliacora triandra extract; 5,7-dihydroxy-6-oxoheptadecanoic acid; liraglutide; enalapril; canagliflozin; isoprenaline; Liuwei Dihuang pill; streptozotocin; six novel poricoic acids from Poria cocos; poricoic acid ZM; poricoic acid ZP; secolanostane tetracyclic triterpenoids; Chuanxiong Rhizoma; Myricanone; Wallichilide; Sitosterol; Chloroquine; Amodiaquine; Streptozotocin; statins; atorvastatin; Allopurinol; febuxostat; Terminalia bellerica; saxagliptin; Adriamycin; baru almond oil; mineral oil; Epicatechin; 2,3-dihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid; 3-hydroxyphenylpropionic acid; Sauchinone; Shenkang VII recipe; porcine collagen hydrolysate; prolyl-hydroxyproline; APX-115; sodium nitrite; isoquercetin; topiroxostat; siXDH; Ginkgo biloba extract; Streptozotocin |
| Mechanism: | |
| Reference (PMIDs): | 31454063; 31544222; 31549412; 31625434; 31683056; 31697931; 31740151; 31755322; 31795780; 31876965; 31881376; 31883830; 31940200; 31953719; 31982108; 32000387; 32000425; 32000547; 32004509; 32005442; 32012145; 32014572; 32015680; 32028854; 32052153; 32061840; 32066115; 32068124; 32096161; 32103732; 32108627; 32112899; 32124701; 32164457; 32167414; 32192334; 32204978; 32215271; 32240615; 32299536; 32337656; 32339782; 32344355; 32359778; 32360619; 32378178; 32388828; 32391934; 32416450; 32422339; 32432445; 32432759; 32444604; 32446112; 32508843; 32526852; 32534886; 32543455; 32593209; 32605460; 32621069; 32631974; 32651445; 32670409; 32679269; 32680573; 32698907; 32703116; 32726508; 32746936; 32764782; 32798559; 32812781; 32822114; 32831998; 32842976; 32844923; 32860100; 32870362; 32875596; 32877912; 32887916; 32914833; 32920287; 32922187; 32924342; 32929357; 32933504; 32948146; 32951729; 32959859; 32977573; 32980902; 32981311; 33011273; 33023894; 33050202; 33068650 |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D001 | Leuprolide | small molecule | DB00007 | Details | |||
| D010 | Arginine | small molecule | DB00125 | Details | |||
| D046 | Bortezomib | small molecule | DB00188 | Details | |||
| D066 | Doxycycline | small molecule | DB00254 | Details | |||
| D082 | Chlorthalidone | small molecule | DB00310 | Details | |||
| D121 | Zolpidem | small molecule | DB00425 | Details | |||
| D134 | Amikacin | small molecule | DB00479 | Details | |||
| D135 | Lenalidomide | small molecule | DB00480 | Details | |||
| D172 | Nafcillin | small molecule | DB00607 | Details | |||
| D179 | Niacin | small molecule | DB00627 | Details |
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R0001 | DB00007 | approved; investigational | small molecule | Leuprolide | Details | |
| R0010 | DB00125 | investigational; nutraceutical | small molecule | Arginine | Details | |
| R0046 | DB00188 | approved; investigational | small molecule | Bortezomib | Details | |
| R0066 | DB00254 | approved; investigational; vet_approved | small molecule | Doxycycline | Details | |
| R0082 | DB00310 | approved | small molecule | Chlorthalidone | Details | |
| R0121 | DB00425 | approved | small molecule | Zolpidem | Details | |
| R0134 | DB00479 | approved; investigational; vet_approved | small molecule | Amikacin | Details | |
| R0135 | DB00480 | approved | small molecule | Lenalidomide | Details | |
| R0172 | DB00607 | approved; investigational | small molecule | Nafcillin | Details | |
| R0179 | DB00627 | approved; investigational; nutraceutical | small molecule | Niacin | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00025 | 11443197 | J Clin Endocrinol Metab | Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? | Details |
| A00027 | 11533494 | Science | Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. | Details |